Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VDR | P11473 | 12/20 | 0.76 |
| ▸ | MAPT | P10636 | 3/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.65 |
| ▸ | SREBF1 | P36956 | 1/20 | 0.65 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.64 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.64 |
| ▸ | GC | P02774 | 1/20 | 0.64 |
| ▸ | PGR | P06401 | 1/20 | 0.64 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.64 |
| ▸ | RXRA | P19793 | 1/20 | 0.64 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.64 |
| ▸ | CNR1 | P21554 | 1/20 | 0.64 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.64 |
| ▸ | HTR2C | P28335 | 1/20 | 0.64 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.64 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.64 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.64 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.64 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.64 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14107799 | 0.96 | VDR (0.77) | VDRMAPTSMN1; SMN2SREBF1NR1I2 | |
| SCHEMBL23359143 | 0.93 | VDR (0.81) | VDRMAPTSMN1; SMN2SREBF1NR1I2 | |
| SCHEMBL23359142 | 0.93 | VDR (0.81) | VDRMAPTSMN1; SMN2SREBF1NR1I2 | |
| SCHEMBL13993786 | 0.90 | VDR (0.80) | VDRMAPTSMN1; SMN2SREBF1NR1I2 | |
| SCHEMBL6259692 | 0.89 | VDR (0.78) | VDRMAPTSMN1; SMN2SREBF1NR1I2 | |
| SCHEMBL6364731 | 0.89 | VDR (0.78) | VDRMAPTSMN1; SMN2SREBF1NR1I2 | |
| SCHEMBL8003696 | 0.89 | VDR (0.78) | VDRMAPTSMN1; SMN2SREBF1NR1I2 | |
| SCHEMBL8003699 | 0.89 | VDR (0.78) | VDRMAPTSMN1; SMN2SREBF1NR1I2 | |
| SCHEMBL19461421 | 0.88 | VDR (0.82) | VDRMAPTSMN1; SMN2SREBF1NR1I2 | |
| SCHEMBL15371115 | 0.88 | VDR (0.82) | VDRMAPTSMN1; SMN2SREBF1NR1I2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4570321-A2 | JAK INHIBITOR WITH A VITAMIN D ANALOG FOR TREATMENT OF SKIN DISEASES | Incyte Corporation (US) | 2025-06-18 | — | — | EP | disclosed |
| US-20250049817-A1 | JAK INHIBITOR WITH A VITAMIN D ANALOG FOR TREATMENT OF SKIN DISEASES | INCYTE CORP (US) | 2025-02-13 | — | — | US | disclosed |
| US-12005067-B2 | JAK inhibitor with a vitamin D analog for treatment of skin diseases | INCYTE CORPORATION (US) | 2024-06-11 | — | — | US | disclosed |
| CN-117157080-A | JAK inhibitors containing vitamin D analogues for the treatment of skin disorders | 因赛特公司 | 2023-12-01 | — | — | CN | disclosed |
| EP-4255442-A1 | JAK INHIBITOR WITH A VITAMIN D ANALOG FOR TREATMENT OF SKIN DISEASES | Incyte Corporation (US) | 2023-10-11 | — | — | EP | disclosed |
| WO-2023068322-A1 | CD RING SIDE CHAIN-SUBSTITUTED VITAMIN D DERIVATIVE | 学校法人帝京大学 | 2023-04-27 | — | — | WO | disclosed |
| US-20220202834-A1 | JAK INHIBITOR WITH A VITAMIN D ANALOG FOR TREATMENT OF SKIN DISEASES | INCYTE CORPORATION | 2022-06-30 | — | — | US | disclosed |
| WO-2022120131-A1 | JAK INHIBITOR WITH A VITAMIN D ANALOG FOR TREATMENT OF SKIN DISEASES | INCYTE CORPORATION (US) | 2022-06-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12005067-B2 | JAK inhibitor with a vitamin D analog for treatment of skin diseases | JAK3, IL23R, JAK1 | VDR 4/4885MAPT 1458/4885SMN1; SMN2 4723/4885 |
| US-20250049817-A1 | JAK INHIBITOR WITH A VITAMIN D ANALOG FOR TREATMENT OF SKIN DISEASES | JAK3, IL23R, JAK1 | VDR 4/4885MAPT 1458/4885SMN1; SMN2 4723/4885 |
| US-20220202834-A1 | JAK INHIBITOR WITH A VITAMIN D ANALOG FOR TREATMENT OF SKIN DISEASES | JAK3, IL23R, JAK1 | VDR 4/4885MAPT 1458/4885SMN1; SMN2 4723/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.